Top 10 BioTech Startups in india
India’s biotech industry is thriving with numerous innovative startups making significant contributions to healthcare, agriculture, and environmental sustainability. Here are ten prominent biotech startups in India:
These startups are at the forefront of biotechnology in India, driving advancements in healthcare, sustainable energy, and genetic research, and contributing to the global biotech landscape.
Serum Institute of India – Based in Pune and founded in 1966, it is the world’s largest vaccine producer, known for its significant role in developing Covishield in collaboration with Oxford University and AstraZeneca (VieStories).
| Attribute | Details |
|---|---|
| Name | Serum Institute of India |
| Founded | 1966 |
| Founder | Cyrus Poonawalla |
| Headquarters | Pune, Maharashtra, India |
| Industry | Biotechnology, Pharmaceuticals |
| Primary Products | Vaccines, immunobiologicals |
| Notable Achievements | World’s largest vaccine producer by volume; developer of Covishield (COVID-19 vaccine) in collaboration with Oxford University and AstraZeneca【9†source】 |
| Key Products | Covishield (COVID-19 vaccine), vaccines for diseases like diphtheria, tetanus, and hepatitis B |
| Collaborations | AstraZeneca, Oxford University |
| Market Reach | Global presence, supplying vaccines to over 140 countries |
| Revenue | Not publicly disclosed, but significant due to global vaccine distribution |
| Employee Count | Over 7000 employees |
| Website | seruminstitute.com |
Overview
The Serum Institute of India is a pivotal player in the global vaccine market. Founded by Dr. Cyrus Poonawalla in 1966, it has grown to become the world’s largest vaccine manufacturer by volume. The company’s extensive portfolio includes vaccines for a variety of infectious diseases such as diphtheria, tetanus, and hepatitis B.
Key Contributions
During the COVID-19 pandemic, the Serum Institute played a crucial role by developing Covishield in partnership with AstraZeneca and Oxford University. This vaccine has been a cornerstone of vaccination efforts in many countries, particularly in the developing world【9†source】.
Market Impact
The Serum Institute’s contributions extend beyond COVID-19, with a broad range of vaccines that are critical to global public health. Its vaccines are used in national immunization programs and have a significant impact on disease prevention worldwide.
For more information, you can visit their official website.
Biocon – Located in Bangalore, Biocon was founded in 1978 and is renowned for its innovations in healthcare, especially in the development of biosimilars, insulin, and oncology products (VieStories).
| Attribute | Details |
|---|---|
| Name | Biocon |
| Founded | 1978 |
| Founder | Kiran Mazumdar-Shaw |
| Headquarters | Bangalore, Karnataka, India |
| Industry | Biotechnology, Pharmaceuticals |
| Primary Products | Biosimilars, generics, insulin, oncology products, immunosuppressants |
| Notable Achievements | First Indian company to receive USFDA approval for biosimilars; major player in global insulin market |
| Key Products | Insulin Glargine (Basaglar), Trastuzumab (Herceptin biosimilar), Pegfilgrastim (Neulasta biosimilar) |
| Collaborations | Mylan, Sandoz, Bristol-Myers Squibb |
| Market Reach | Over 120 countries |
| Revenue | Approx. $1 billion USD (as of 2023) |
| Employee Count | Over 14,000 employees |
| Website | biocon.com |
Overview
Biocon, founded by Kiran Mazumdar-Shaw in 1978, is one of India’s leading biotechnology companies. The company started as an enzyme manufacturing firm and has evolved into a global biopharmaceutical enterprise. Biocon focuses on developing biosimilars, generic formulations, and novel biologics for various therapeutic areas including diabetes, oncology, and immunology【9†source】【7†source】.
Key Contributions
Biocon has been a pioneer in the biotechnology industry, especially in the development of biosimilars. It was the first Indian company to receive USFDA approval for biosimilars, and it has a strong presence in the global insulin market. Biocon’s biosimilar Trastuzumab, marketed as Kanjinti, has been a significant milestone in providing affordable cancer treatment【7†source】.
Market Impact
Biocon’s products are marketed in over 120 countries, making it a major player in the global biopharmaceutical market. The company’s collaborations with major pharmaceutical companies like Mylan and Sandoz have further strengthened its market position and expanded its global reach【9†source】【8†source】.
For more information, you can visit their official website.
MedGenome – Founded in 2013 and headquartered in Bangalore, MedGenome focuses on genomics-based diagnostics and research, providing personalized genetic testing and contributing significantly to precision medicine (StartupTalky) (BioTecNika).
| Attribute | Details |
|---|---|
| Name | MedGenome |
| Founded | 2013 |
| Founder | Sam Santhosh |
| Headquarters | Bangalore, Karnataka, India |
| Industry | Genomics, Biotechnology |
| Primary Products | Genetic testing services, genomic data analysis |
| Notable Achievements | Leading provider of genomics-based diagnostics and research in India |
| Key Products | Genetic tests for inherited diseases, cancer genomics, non-invasive prenatal testing (NIPT) |
| Collaborations | Academic institutions, research organizations, healthcare providers |
| Market Reach | India, Southeast Asia, Middle East, Africa |
| Revenue | Not publicly disclosed, significant due to expanding market reach and collaborations |
| Employee Count | Over 500 employees |
| Website | medgenome.com |
Overview
MedGenome, founded by Sam Santhosh in 2013, is a leading genomics and biotechnology company based in Bangalore. It focuses on genomics-based diagnostics and research, advancing the field of precision medicine through cutting-edge genomics technologies. The company provides a wide range of genetic testing services and generates genomic data for research purposes【8†source】【9†source】.
Key Contributions
MedGenome is renowned for its genetic testing services, which include tests for inherited diseases, cancer genomics, and non-invasive prenatal testing (NIPT). The company’s work in genomics-based diagnostics has significantly contributed to the advancement of personalized medicine in India. MedGenome also collaborates with various academic institutions and research organizations to drive forward genomics research【8†source】【7†source】.
Market Impact
MedGenome has established a strong presence in India and expanded its services to Southeast Asia, the Middle East, and Africa. Its collaborations with healthcare providers and research institutions have helped it to become a major player in the genomics industry, providing critical data and insights for medical research and diagnostics【7†source】【9†source】.
For more information, you can visit their official website.
Bugworks Research – This Bangalore-based company, founded in 2014, is dedicated to combating antibiotic resistance through the development of novel antibiotics and antimicrobial solutions (BioTecNika).
| Attribute | Details |
|---|---|
| Name | Bugworks Research |
| Founded | 2014 |
| Founders | Anand Anandkumar, V Balasubramanian, Pavan Silawal, Nagaswami Vasantha |
| Headquarters | Bangalore, Karnataka, India |
| Industry | Biotechnology, Pharmaceuticals |
| Primary Focus | Antibiotic research, antimicrobial resistance |
| Notable Achievements | Developing novel antibiotics to combat drug-resistant bacteria |
| Key Products | Broad-spectrum antibiotics targeting multi-drug-resistant bacterial infections |
| Collaborations | Indian and international pharmaceutical companies, research institutions |
| Market Reach | Global, with focus on markets heavily impacted by antimicrobial resistance |
| Revenue | Not publicly disclosed |
| Employee Count | Over 50 employees |
| Website | bugworksresearch.com |
Overview
Bugworks Research, founded in 2014, is a pioneering biotechnology company based in Bangalore. It focuses on addressing the global health challenge posed by antimicrobial resistance (AMR). The company is dedicated to developing new classes of broad-spectrum antibiotics that can combat multi-drug-resistant bacterial infections【8†source】【9†source】.
Key Contributions
Bugworks Research is at the forefront of antibiotic innovation. The company’s proprietary technology aims to create antibiotics that are effective against a wide range of drug-resistant bacteria. This work is crucial in the fight against superbugs, which pose a significant threat to global health. Bugworks has also received recognition and support from various international health organizations and research institutions for its contributions to this critical area of medical research【8†source】【9†source】.
Market Impact
With its focus on developing new antibiotics, Bugworks Research addresses a pressing need in the healthcare industry. The company’s innovations have the potential to significantly impact global health by providing effective treatments for infections that are currently difficult to treat due to antibiotic resistance. Their research and development efforts are supported by collaborations with major pharmaceutical companies and research institutions worldwide【8†source】.
For more information, you can visit their official website.
Sea6 Energy – Founded in 2010 and located in Bangalore, Sea6 Energy specializes in marine biotechnology, focusing on the production of seaweed-based biofuels and other sustainable energy solutions (StartupTalky) (BioTecNika).
| Attribute | Details |
|---|---|
| Name | Sea6 Energy |
| Founded | 2010 |
| Founders | Shriram Vasudevan, Madhu Pai, Saravanan Sampath, Saurabh Agarwal, Siddharth Narayan, Vardhan Patankar |
| Headquarters | Bangalore, Karnataka, India |
| Industry | Biotechnology, Sustainable Energy |
| Primary Focus | Marine biotechnology, seaweed-based biofuels |
| Notable Achievements | Pioneering sustainable energy solutions through marine resources |
| Key Products | Seaweed-based biofuels, biostimulants, animal feed additives |
| Collaborations | Academic institutions, research organizations, environmental groups |
| Market Reach | India and international markets |
| Revenue | Not publicly disclosed |
| Employee Count | Over 100 employees |
| Website | sea6energy.com |
Overview
Sea6 Energy, founded in 2010, is a biotechnology company based in Bangalore that specializes in marine biotechnology. The company harnesses the potential of seaweed to create sustainable solutions for energy production, agriculture, and animal feed. Sea6 Energy is at the forefront of developing environmentally friendly technologies that address global energy challenges【8†source】【9†source】.
Key Contributions
Sea6 Energy is known for its innovative approach to using marine biomass, particularly seaweed, to produce biofuels and other sustainable products. The company’s technologies are designed to convert seaweed into biofuels, biostimulants for agriculture, and additives for animal feed. This not only provides a renewable energy source but also contributes to reducing carbon emissions and promoting sustainable agricultural practices【8†source】【9†source】.
Market Impact
The company’s work has significant implications for both energy and agriculture. By providing sustainable alternatives to fossil fuels and chemical fertilizers, Sea6 Energy’s products help mitigate the impact of climate change and promote environmental sustainability. Their collaborations with research institutions and environmental groups further enhance their ability to innovate and expand their market reach【8†source】【9†source】.
For more information, you can visit their official website.
Mapmygenome – Based in Hyderabad and founded in 2013, Mapmygenome offers personalized genetic testing and health analytics, integrating genetics with lifestyle factors to provide holistic health recommendations (BioTecNika).
| Attribute | Details |
|---|---|
| Name | Mapmygenome |
| Founded | 2013 |
| Founder | Anu Acharya |
| Headquarters | Hyderabad, Telangana, India |
| Industry | Genomics, Biotechnology |
| Primary Products | Genetic testing services, personal genomics |
| Notable Achievements | Leading provider of direct-to-consumer genetic testing in India |
| Key Products | Genomepatri (comprehensive genomic testing), Oncomap (cancer risk assessment), Cardiomap (heart disease risk assessment) |
| Collaborations | Healthcare providers, research institutions, academic organizations |
| Market Reach | India, with growing international presence |
| Revenue | Not publicly disclosed |
| Employee Count | Over 100 employees |
| Website | mapmygenome.in |
Overview
Mapmygenome, founded in 2013 by Anu Acharya, is a pioneering genomics company based in Hyderabad. The company offers a wide range of genetic testing services aimed at providing individuals with insights into their genetic makeup and associated health risks. Their goal is to promote preventive healthcare by enabling people to understand their genetic predispositions【7†source】【8†source】.
Key Contributions
Mapmygenome is best known for its flagship product, Genomepatri, a comprehensive genomic testing service that provides insights into an individual’s ancestry, traits, and health risks. Other notable products include Oncomap, which assesses genetic risk for various cancers, and Cardiomap, which evaluates the risk of heart disease. These products help individuals make informed decisions about their health and lifestyle【7†source】【9†source】.
Market Impact
Mapmygenome has significantly impacted the personal genomics market in India by making genetic testing accessible and affordable. The company’s services are utilized by healthcare providers and researchers, and they have formed collaborations with academic institutions to advance genetic research. This has positioned Mapmygenome as a leader in the field of genomics and personalized healthcare in India【8†source】【9†source】.
For more information, you can visit their official website.
Zumutor Biologics – Established in 2013 in Bangalore, this startup focuses on immunotherapy and antibody-based therapies, developing precision-targeting antibodies for cancer treatment (BioTecNika).
| Attribute | Details |
|---|---|
| Name | Zumutor Biologics |
| Founded | 2013 |
| Founder | Kavitha Iyer Rodrigues |
| Headquarters | Bangalore, Karnataka, India |
| Industry | Biotechnology, Immuno-oncology |
| Primary Focus | Immunotherapy, antibody-based therapies |
| Notable Achievements | Developing novel antibody-based immunotherapies for cancer treatment |
| Key Products | NK cell therapeutics, monoclonal antibodies targeting cancer cells |
| Collaborations | Academic institutions, research organizations, pharmaceutical companies |
| Market Reach | India and international markets |
| Revenue | Not publicly disclosed |
| Employee Count | Over 50 employees |
| Website | zumutor.com |
Overview
Zumutor Biologics, founded in 2013 by Kavitha Iyer Rodrigues, is a biotechnology company based in Bangalore. The company focuses on the development of novel immunotherapies, particularly NK (Natural Killer) cell therapeutics and monoclonal antibodies, aimed at treating various types of cancer. Zumutor’s innovations are contributing to the advancement of precision medicine in oncology【8†source】【9†source】.
Key Contributions
Zumutor Biologics is known for its work in immuno-oncology, specifically in developing therapies that enhance the body’s immune response to cancer. Their pipeline includes NK cell-based therapies and monoclonal antibodies that target and destroy cancer cells. These cutting-edge therapies have the potential to provide more effective and personalized treatment options for cancer patients【7†source】【8†source】.
Market Impact
The company’s research and development efforts are aimed at addressing unmet needs in cancer treatment. Zumutor’s collaborations with academic institutions, research organizations, and pharmaceutical companies enhance its ability to innovate and bring new therapies to market. Their work is recognized both in India and internationally, contributing to the global fight against cancer【8†source】【9†source】.
For more information, you can visit their official website.
Forus Health – Founded in 2010 in Bangalore, Forus Health develops innovative ophthalmic devices aimed at eliminating preventable blindness through intelligent pre-screening techniques (StartupTalky) (VieStories).
| Attribute | Details |
|---|---|
| Name | Forus Health |
| Founded | 2010 |
| Founders | K. Chandrasekhar, Shyam Vasudevarao |
| Headquarters | Bangalore, Karnataka, India |
| Industry | Healthcare, Medical Devices |
| Primary Focus | Ophthalmic medical devices |
| Notable Achievements | Development of affordable and innovative eye care solutions to prevent blindness |
| Key Products | 3nethra Classic (comprehensive eye screening device), 3nethra Neo (retinal imaging for neonates), 3nethra Flora (corneal imaging) |
| Collaborations | Hospitals, clinics, eye care institutions |
| Market Reach | Over 25 countries |
| Revenue | Not publicly disclosed |
| Employee Count | Over 100 employees |
| Website | forushealth.com |
Overview
Forus Health, founded in 2010 by K. Chandrasekhar and Shyam Vasudevarao, is a healthcare technology company based in Bangalore. The company specializes in developing affordable and innovative medical devices for ophthalmic care. Their products aim to eliminate preventable blindness by enabling early detection and diagnosis of eye conditions【6†source】【9†source】.
Key Contributions
Forus Health’s flagship product, the 3nethra Classic, is a portable device designed for comprehensive eye screening. It is capable of detecting common eye problems such as cataracts, diabetic retinopathy, glaucoma, and corneal issues. The company also offers specialized devices like the 3nethra Neo, which focuses on retinal imaging for neonates, and the 3nethra Flora, designed for corneal imaging. These products are crucial in providing accessible eye care, particularly in remote and underserved areas【7†source】【8†source】.
Market Impact
Forus Health has made significant strides in the global healthcare market, with its devices being used in over 25 countries. Their innovative solutions have improved eye care accessibility and affordability, particularly in regions lacking advanced medical infrastructure. By partnering with hospitals, clinics, and eye care institutions, Forus Health continues to expand its impact and reach, contributing to the reduction of preventable blindness worldwide【6†source】【9†source】.
For more information, you can visit their official website.
Vyome Therapeutics – This New Delhi-based company, founded in 2010, specializes in dermatology and infectious disease therapeutics, developing novel treatments for drug-resistant infections and skin disorders (BioTecNika).
| Attribute | Details |
|---|---|
| Name | Vyome Therapeutics |
| Founded | 2010 |
| Founders | Shiladitya Sengupta, Rajeev Mantri, Ashutosh Valani, and Vikas Chauhan |
| Headquarters | New Delhi, India |
| Industry | Biotechnology, Pharmaceuticals |
| Primary Focus | Dermatology, infectious diseases |
| Notable Achievements | Development of novel treatments for drug-resistant dermatological conditions |
| Key Products | VB-1953 (topical treatment for acne), VB-611 (antimicrobial for skin infections) |
| Collaborations | Academic institutions, pharmaceutical companies, research organizations |
| Market Reach | India and international markets |
| Revenue | Not publicly disclosed |
| Employee Count | Over 50 employees |
| Website | vyometx.com |
Overview
Vyome Therapeutics, founded in 2010, is a clinical-stage specialty biopharmaceutical company based in New Delhi. It focuses on developing innovative therapies for dermatological conditions and drug-resistant infections. The company leverages its deep expertise in microbiology and dermatology to address unmet medical needs in these areas【8†source】【9†source】.
Key Contributions
Vyome Therapeutics is known for its pioneering work in treating drug-resistant skin infections and other dermatological conditions. The company’s lead product, VB-1953, is a topical treatment for acne, particularly targeting antibiotic-resistant strains of bacteria. Another notable product is VB-611, designed to treat various skin infections with a novel antimicrobial approach. These therapies represent significant advancements in dermatological care, especially in the context of rising antimicrobial resistance【8†source】【9†source】.
Market Impact
Vyome Therapeutics aims to make a substantial impact on the global dermatology market by providing effective treatments for conditions that are increasingly becoming resistant to existing therapies. Through collaborations with academic institutions and pharmaceutical companies, Vyome continues to innovate and expand its product pipeline. Its contributions are not only significant for patient care in India but also have the potential to benefit international markets facing similar challenges【7†source】【9†source】.
For more information, you can visit their official website.
Bharat Biotech – Founded in 1996 in Hyderabad, Bharat Biotech is known for its extensive work in vaccine development, including Covaxin, which was a crucial vaccine during the COVID-19 pandemic (StartupTalky).
Certainly! Here is a table summarizing key information about Bharat Biotech:
| Aspect | Details |
|---|---|
| Founded | 1996 |
| Founders | Dr. Krishna Ella and Mrs. Suchitra Ella |
| Headquarters | Hyderabad, Telangana, India |
| Focus Areas | Vaccines, Biotherapeutics, Biotechnology |
| Flagship Product | Covaxin (COVID-19 vaccine) |
| Research Areas | Virology, Bacteriology, Immunology, Recombinant DNA Technology |
| Facilities | State-of-the-art facilities for vaccine manufacturing and biotechnology R&D |
| Global Presence | Exports vaccines to over 123 countries, presence in Asia, Africa, Latin America |
| Collaborations | Collaborates with international organizations, research institutions, and pharmaceutical companies |
| Vaccine Portfolio | Covaxin, Rotavirus, Japanese Encephalitis, Rabies, Typhoid, and others |
| Quality Standards | Adheres to global quality standards for safety, efficacy, and ethical practices |
| Impact | Significant contributions to global health, particularly in disease prevention through vaccines |
This table provides a snapshot of Bharat Biotech’s background, focus areas, products, collaborations, and impact in the biotechnology and vaccine development sectors.
Bharat biotech: Top 10 BioTech Startups in india
